|
|
 |
Case Study: Arrowhead’s Acquisition of Roche’s siRNA Delivery Technology Platform
Volume 8, Issue 4
Authors:
John Miller
Abstract:
In fall 2011, Arrowhead Research Corporation announced that it had acquired Roche’s RNA interference (RNAi) business previously known as Roche RNA Therapeutics. In this article, Nanotechnology Law & Business Managing Editor John Miller reviews the structure of the transaction, provides an overview of the technology, and explains why this deal is likely to have a major impact on Arrowhead’s future as well as the future of siRNA.
Full Text (PDF)
|
|
